This report sample provides an overview of the 30 Gene Therapy-relevant abstracts presented at the meeting, including details on therapeutic class, disease indications, safety results and much more. The report includes the listed abstracts with direct links and links to the related drug or trial record on Beacon, as well as some additional analysis.
We hope that you find this report informative and insightful and that you share our excitement about the latest developments in the Gene Therapy field.
This Pre-Conference Planner is a comprehensive list of abstracts that will be presented during the conference. The abstracts are categorized separately under clinical trial and preclinical drug data. Additionally, it includes abstracts that are either under embargo or require further information before being allocated to the correct Beacon page. Each abstract comes with its own link that takes you to the associated trial or drug page on Beacon wherever available.
Beacon Gene Therapy
How the most complete gene therapy database can help you
What we cover
We included trial and drug records for preclinical, active, approved, and discontinued:
- RNA/DNA Viral vector-based therapies
- DNA Non-viral vector-based therapies
- Genetically Modified cell therapies
- Empty Vector Trials
- Other comparable modalities within gene therapy, whether cell-free or cell-based
- Beacon Gene Therapy covers all genetically driven non-oncology indications that utilize gene therapy to mediate the condition.
How Beacon Gene Therapy works
Search the clinical trial and drug landscape by gene/mutation, editing technology (CRISPR/Cas9, Cas-CLOVER, etc.), gene delivery system, promoter, etc., instantaneously and/or extract the data points you need to conduct more complex analysis.
Our unique Milestones filter and visualization highlights past, present, and future drug development milestones including drug and trial readouts, asset history, and regulatory announcements. This enhancement provides an accurate, timely and exhaustive single-drug timeline allowing you to benchmark progress in the gene therapy space.
If publicly available, information regarding immunogenicity is included (unique to Beacon Gene Therapy)